• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Alpha Teknova Inc (NQ: TKNO )

    7.160 +0.270 (+3.92%)
    Streaming Delayed Price Updated: 4:00 PM EST, Nov 8, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Alpha Teknova Inc

    < Previous 1 2 Next >
    Teknova Reports Third Quarter 2024 Financial Results
    From Alpha Teknova, Inc.
    Via GlobeNewswire
    Teknova to Report Third Quarter 2024 Financial Results on November 7, 2024
    From Alpha Teknova, Inc.
    Via GlobeNewswire
    Teknova Reports Second Quarter 2024 Financial Results
    From Alpha Teknova, Inc.
    Via GlobeNewswire
    Teknova Introduces Proprietary Express-Tek℠ Production Service and Expanded Manufacturing Grade Options to Expedite Novel Therapy Development
    From Alpha Teknova, Inc.
    Via GlobeNewswire
    Sidoti Events, LLC's Virtual August Micro-Cap Conference
    Via ACCESSWIRE
    Teknova to Report Second Quarter 2024 Financial Results on August 13, 2024
    From Alpha Teknova, Inc.
    Via GlobeNewswire
    Teknova Announces Closing of $15.4 Million Private Placement
    From Alpha Teknova, Inc.
    Via GlobeNewswire
    Teknova Announces $15.4 Million Private Placement
    From Alpha Teknova, Inc.
    Via GlobeNewswire
    Teknova Provides Strategic Business Update and Announces Preliminary Second Quarter 2024 Results
    From Alpha Teknova, Inc.
    Via GlobeNewswire
    Teknova Reports First Quarter 2024 Financial Results
    From Alpha Teknova, Inc.
    Via GlobeNewswire
    Teknova Launches Proprietary Build-Tek™ Solutions Custom Configurator and Latest AAV-Tek™ Product to Further Accelerate Novel Therapy Development
    From Alpha Teknova, Inc.
    Via GlobeNewswire
    Teknova to Report First Quarter 2024 Financial Results on May 13, 2024
    From Alpha Teknova, Inc.
    Via GlobeNewswire
    Teknova Reports Fourth Quarter and Full Year 2023 Financial Results
    From Alpha Teknova, Inc.
    Via GlobeNewswire
    Teknova to Report Fourth Quarter and Full Year 2023 Financial Results on March 11, 2024
    From Alpha Teknova, Inc.
    Via GlobeNewswire
    3 cheap stocks that insiders are buying
    The stocks with the most active insider buying changed over the last month putting three new names in the spotlight; all are trading near historic lows. 
    Via MarketBeat
    Topics Initial Public Offering
    Exposures Securities Market
    Teknova Reports Third Quarter 2023 Financial Results
    From Alpha Teknova, Inc.
    Via GlobeNewswire
    Teknova to Report Third Quarter 2023 Financial Results on November 9, 2023
    From Alpha Teknova, Inc.
    Via GlobeNewswire
    Teknova Launches Latest Proprietary AAV-Tek™ Product and End-to-End Plasmid Workflow Solutions to Streamline Therapeutic Process Development
    Novel AEX screening kit – now available for AAV6 – and an expansive suite of high-quality reagents designed to expedite plasmid production will help accelerate breakthroughs across multiple AAV... 
    From Alpha Teknova, Inc.
    Via GlobeNewswire
    Teknova Announces Closing of $22.9 Million Concurrent Registered Direct Offering and Private Placement and Amends Credit Facility
    From Alpha Teknova, Inc.
    Via GlobeNewswire
    Teknova Announces Up to $22.9 Million Concurrent Registered Direct Offering and Private Placement
    From Alpha Teknova, Inc.
    Via GlobeNewswire
    Teknova Announces New Board Member, Martha J. Demski
    From Alpha Teknova, Inc.
    Via GlobeNewswire
    Teknova Reports Second Quarter 2023 Financial Results
    From Alpha Teknova, Inc.
    Via GlobeNewswire
    Teknova Announces Opening of New GMP-Certified Facility, Increasing Manufacturing Capacity for Custom, High-Quality Life Sciences Reagents
    State-of-the-art facility in Hollister, California is designed to help bioprocessing and gene therapy companies scale from research to clinical production 
    From Alpha Teknova, Inc.
    Via GlobeNewswire
    Teknova to Report Second Quarter 2023 Financial Results on August 10, 2023
    From Alpha Teknova, Inc.
    Via GlobeNewswire
    Teknova and Sartorius BIA Separations Share Data Demonstrating Reliable and Scalable Approach for the Enhancement of AAV Full Capsid Enrichment with an Optimized AEX Platform
    Results from the companies’ first collaboration show the successful achievement of more than 85% full AAV with 80-95% recoveries when pairing Sartorius BIA Separations’ monolithic purification platform... 
    From Alpha Teknova, Inc.
    Via GlobeNewswire
    Teknova Expands Proprietary AAV-Tek™ Solutions Product Line to Deliver End-to-End Solutions for Gene Therapy Process Development
    First-of-its-kind screening kit now available for AAV8 – along with a suite of high-quality reagents to support the entire AAV workflow – helping gene therapy developers save months in process... 
    From Alpha Teknova, Inc.
    Via GlobeNewswire
    Teknova to Participate in Upcoming Investor Conference
    From Alpha Teknova, Inc.
    Via GlobeNewswire
    Teknova Reports First Quarter 2023 Financial Results
    From Alpha Teknova, Inc.
    Via GlobeNewswire
    Teknova to Present Data on Novel Products to Accelerate the Development of AAV Therapies at ASGCT 2023 Annual Meeting
    Company will share their latest findings for custom product innovations aimed at addressing key gene therapy bioprocessing bottlenecks 
    From Alpha Teknova, Inc.
    Via GlobeNewswire
    Teknova Announces Time Change for First Quarter 2023 Financial Results Conference Call on May 10, 2023
    From Alpha Teknova, Inc.
    Via GlobeNewswire
    < Previous 1 2 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.